Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017. https://doi.org/10.1016/j.eururo.2016.06.010.

Article  PubMed  Google Scholar 

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013. https://doi.org/10.1016/j.eururo.2012.07.033.

Article  PubMed  Google Scholar 

Somuncu B, Keskin S, Antmen FM, Saglican Y, Ekmekcioglu A, Ertuzun T, et al. Non-muscle invasive bladder cancer tissues have increased base excision repair capacity. Sci Rep. 2020. https://doi.org/10.1038/s41598-020-73370-z.

Article  PubMed  PubMed Central  Google Scholar 

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; https://doi.org/10.1016/j.eururo.2011.03.017.

Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In Situ) - 2019 update. Eur Urol. 2019. https://doi.org/10.1016/j.eururo.2019.08.016

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016. https://doi.org/10.1016/j.juro.2016.06.049.

Article  PubMed  PubMed Central  Google Scholar 

Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161(4):1124–7.

Article  PubMed  Google Scholar 

Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy–an overview. Curr Radiopharm. 2013. https://doi.org/10.2174/18744710113066660023.

Article  PubMed  Google Scholar 

Hoefnagel CA. Radionuclide cancer therapy. Ann Nucl Med. 1998. https://doi.org/10.1007/BF03164831.

Article  PubMed  Google Scholar 

Fortin MA, Orlova A, Malmström PU, Tolmachev V. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342–3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med. 2007. https://doi.org/10.3892/ijmm.19.2.285.

Article  PubMed  Google Scholar 

Lotan R, Raz A. Lectins in cancer cells. Ann N Y Acad Sci. 1988. https://doi.org/10.1111/j.1749-6632.1988.tb22372.x.

Article  PubMed  Google Scholar 

Monsigny M, Roche AC, Midoux P. Endogenous lectins and drug targeting. Ann N Y Acad Sci. 1988. https://doi.org/10.1111/j.1749-6632.1988.tb22373.x.

Article  PubMed  Google Scholar 

Wadhwa MS, Rice KG. Receptor mediated glycotargeting. J Drug Target. 1995. https://doi.org/10.3109/10611869509059211.

Article  PubMed  Google Scholar 

Višnjar T, Romih R, Zupančič D. Lectins as possible tools for improved urinary bladder cancer management. Glycobiology. 2019. https://doi.org/10.1093/glycob/cwz001.

Article  PubMed  Google Scholar 

Futami M, Watanabe Y, Asama T, Murata H, Tada H, Kosaka M, et al. Uniformly cationized protein efficiently reaches the cytosol of mammalian cells. Bioconjug Chem. 2012. https://doi.org/10.1021/bc300030d.

Article  PubMed  Google Scholar 

Chinol M, De Cobelli O, Trifirò G, Scardino E, Bartolomei M, Verweij F, et al. Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy. Eur Urol. 2003. https://doi.org/10.1016/S0302-2838(03)00369-5.

Article  PubMed  Google Scholar 

St Clair MB, Sowers AL, Davis JA, Rhodes LL. Urinary bladder catheterization of female mice and rats. Contemp Top Lab Anim Sci. 1999;38(3):78–9.

PubMed  Google Scholar 

Kostou T, Papadimitroulas P, Loudos G, Kagadis GC. A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom. Phys Med Biol. 2016. https://doi.org/10.1088/0031-9155/61/6/2333.

Article  PubMed  Google Scholar 

Sledge DG, Patrick DJ, Fitzgerald SD, Xie Y, Kiupel M. Differences in expression of uroplakin III, cytokeratin 7, and cyclooxygenase-2 in canine proliferative urothelial lesions of the urinary bladder. Vet Pathol. 2015. https://doi.org/10.1177/0300985814522819.

Article  PubMed  Google Scholar 

Matsumoto K, Satoh T, Irie A, Ishii J, Kuwao S, Iwamura M, et al. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 2008. https://doi.org/10.1016/j.urology.2007.11.128.

Article  PubMed  Google Scholar 

Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M, et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell. 2013. https://doi.org/10.1016/j.devcel.2013.07.017.

Article  PubMed  PubMed Central  Google Scholar 

Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004. https://doi.org/10.1111/j.1464-410X.2003.04655.x.

Article  PubMed  Google Scholar 

Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association J Urol. 1999;162(5):1697–701.

Google Scholar 

Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999. https://doi.org/10.3322/canjclin.49.1.33.

Article  PubMed  Google Scholar 

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007.https://doi.org/10.1016/j.juro.2007.09.003.

Golfieri R. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepatic Oncol. 2014. https://doi.org/10.2217/hep.14.6.

Article  Google Scholar 

Birgit P, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical α-radioimmunotherapy with 213 Bi-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009. https://doi.org/10.2967/jnumed.109.065961.

Article  Google Scholar 

Frost SHL, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, et al. Comparative efficacy of 177Lu and 90Y for Anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0120561.

Article  PubMed  PubMed Central  Google Scholar 

Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004. https://doi.org/10.1038/nrd1413.

Article  PubMed  Google Scholar 

Dong C, Yang S, Shi J, Zhao H, Zhong L, Liu Z, et al. SPECT/NIRF Dual modality imaging for detection of intraperitoneal colon tumor with an avidin/biotin pretargeting system. Sci Rep. 2016. https://doi.org/10.1038/srep18905.

Article  PubMed  PubMed Central  Google Scholar 

Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2015. https://doi.org/10.1158/0008-5472.CAN-18-0173.

Article  PubMed  Google Scholar 

Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose–volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010. https://doi.org/10.1016/j.ijrobp.2009.02.090.

Article  PubMed  PubMed Central  Google Scholar